Proteomics potentials...enjoy...-g-
i don't follow too many other companies,,,but you pose a good question. i found a few interesting websites...and a few interesting companies.
healthtech.com
incyte.com
biospace.com
pharmalicensing.com
an interesting article---
biospace.com
Citadel Investment Group: Post-Genomic Investing
Eric Muse is an associate in private investments at Citadel Investment Group (Chicago).
"The most exciting part of biotech right now is genomics, and that's reflected in the astronomical stock prices that we've been seeing. But what a lot of people are missing is that there's a lot of work to be done yet. Okay, so we've nearly identified 3 billion base pairs and 100,000 genes. Now what do we do? Because, the fact is, those 100,000 genes can translate into 1 million proteins, and those 1 million proteins can be expressed in different environments, in different people, and in different disease states. So the next step--proteomics--is going to be an even bigger, more daunting task. For whereas genomics is identifying genes and understanding information about genes, proteomics is identifying the proteins those genes make and understanding the functions those proteins perform.
"Proteomics is the most critical part. Because although you might have a gene that looks like it's implicated in a particular disease, what do you do about it? What proteins does that gene make, and what do those proteins do? That gene could translate into 100 different proteins. How would you determine which protein to go after?
"The companies that are able to solve these problems--the gene-expression companies and the expression analysis companies--are going to be some big players. Right now, I think the best thing going is expression analysis with Gene Logic (Gaithersburg, MD). Its technology isn't perfect, but it's the most cost effective, and it's the most rapid. Going down the road, though, we're going to need something more, something that's more cost effective, and something that's more accurate.
"H&Q is helpful in this regard. So many people within the industry come together, whether its other investors or other colleagues who you can share ideas and information with. Also, you can get up to date on the major companies in the sector, both public and private. Of all the biotech meetings throughout the year, H&Q is the one that I mark on the calendar to make sure I attend."
biospace.com
Vertex Pharmaceuticals (VRTX) To Access Genomic And Proteomic Technologies In Alliance With Harvard Medical School
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has entered into an agreement with Harvard Medical School to accelerate small molecule drug discovery using genomic and proteomic information from Harvard Medical School's Institute of Proteomics. Vertex will use the information as part of its chemogenomics discovery effort, which seeks to design multiple drugs in parallel based on structurally similar targets in gene families.
biospace.com
CYTOGEN (CYTO) Announces Strategic Partnership For Its Subsidiary, AxCell Biosciences; Technology And Marketing Alliance Will Focus On AxCell's Proprietary Proteomics Database
Cytogen Corporation (Nasdaq: CYTO) announced that its wholly owned subsidiary, AxCell Biosciences Corporation (AxCell) and InforMax, Inc. (InforMax) have signed a letter of intent to market AxCell's proprietary proteomics database, currently under development, as part of an enterprise bioinformatics solution to the Pharmaceutical, Biotechnology and Agricultural industries. This agreement represents an important advancement of AxCell's proteomic platform.
biospace.com
Commonwealth Biotechnologies, Inc. (CBTE) Announces Expansion Into Genomics And Proteomics Product Development
Following the addition of several new platform technologies over the last 12 months and a recent alliance with november A G, Erlangen, Germany, Commonwealth Biotechnologies, Inc., (Nasdaq: CBTE) announced today that it will be expanding its R&D effort into the development of genomic and proteomic based products. Although it already holds patents on two of its own products, Heparrest(TM) (a potential human pharmaceutical) and AccuTrac(TM) (a DNA sequencing aid), Commonwealth Biotechnologies' (CBI) major business activity has been that of a contract research organization. In that role, CBI has been providing those same platform technologies and expertise to its clients in the global biotechnology industry
biospace.com
Aurora Biosciences (ABSC) Announces Issuance Of U.S. Patent For New Proteomic Tools For Protein Tagging
Aurora Biosciences Corporation (Nasdaq: ABSC - news) today announced the issuance of U.S. patent number 5,932,474 entitled ``Target Sequences for Synthetic molecules,'' that is directed towards the use of a new protein tagging technology initially developed at the University of California and exclusively licensed to Aurora. A key aspect of this technology is the small ``engineered receptor domain'' genetically encoded in the target protein that enables specific and reversible covalent attachment of a range of novel small molecule tags or optical reporters to the target protein, even in a live cell.
biospace.com
CuraGen (CRGN) To Apply Functional Genomic Technologies To Assemble Proteomic Map Of Drosophila Genome
CuraGen Corporation (Nasdaq: CRGN), an integrated genomics based drug discovery and development company, and the Berkeley Drosophila Genome Project (BDGP) have entered into a collaboration to create the first protein interaction map of the Drosophila melanogaster genome. By discovering and mapping the protein interactions in Drosophila, more commonly known as the fruit fly, scientists will gain tremendous insight into the function of human genes and proteins and how they contribute to the onset of disease. CuraGen expects to publish the results of this collaboration and begin releasing the resulting data to the public later this year.
biospace.com
Lynx Therapeutics (LYNX) Receives Its First Proteomics Patent
Lynx Therapeutics, Inc. (Nasdaq:LYNX - news) announced today the issuance of U.S. patent No. 6,013,165 covering a new technology for separating complex mixtures of proteins. Using solution phase electrophoresis in proprietary micro-channel plates, the technique combines the speed advantages of capillary electrophoresis with the resolving power of two-dimensional (2D) gel-based techniques. It is expected to deliver substantial improvements in sensitivity, reproducibility and throughput. |
